Community Home

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Thank You to JITC Reviewers| Popular Archive Articles Letter from the Editor Hello JITC Readers, Indeed, “ it takes ...

A Message from the President As 2025 draws to a close, I am humbled by the resilience of our community. Throughout the year, many of us faced disruption in our clinics and labs with the uncertain and shifting funding paradigm. However, thanks to ...

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| Popular Archive Articles Letter from the Editor Hello JITC Readers, The recent award of the Nobel Prize in Physiology or Medicine to ...

We are pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2025, Dec. 10–11, 2025. Clinical and translational studies of neoadjuvant pembroluzmab and lenvatinib in patients ...

On December 2, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the tenth computational immuno-oncology webinar of series 5. This webinar discussed patient burden dynamics, serum, tumor ...